久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

澳大利亞Biota 
澳洲藥品開發商Biota宣布其日本伙伴公司已成功研制一種新的抗病毒藥物，僅需一劑即可對抗流感，它在亞洲市場的初步實驗獲得成功。
　　藥品laninamivir對流感具有快速有效的作用，它可能接替瑞沙（Relenza）、達菲（Tamiflu），成為流感的主要藥物。新藥物需要每天服用，可治療甲流感，也可預防流感。
　　Biota主管庫克（Peter Cook）表示，該藥物將在不久后啟動商業供應，它在日本、臺灣、香港和韓國進行的測試顯示藥物安全且有效。臨床實驗的對象有成人也有兒童，只需一個劑量即可消除流感的隱患，而使用達菲則需要每天兩次，總計5天。新藥物對兒童擺脫流感威脅的效果尤為明顯，遠超達菲。
　　Biota的合作伙伴公司Daiichi Sankyo已向日本當局提出申請，計劃在明年讓藥物上市。之后，該藥物將尋求美國和澳洲市場的認可，在這段時間里，它將完成更多的試驗，來保證藥物的安全性。
　　庫克表示，新藥物只需一劑量就可有效對抗季節性流感、禽流感和甲流感。與瑞沙一樣，新藥物需要一種吸入設備，并對兒童的使用存在一些限制。
　　昨日，英國醫學雜志（British medical journal－BMJ）發表的一篇新研究表示，
　　兒童患季節性流感不應給予抗病毒藥物，因為相比它的微小作用，藥物將對兒童產生巨大的副作用。臨床實驗發生，一些服用達菲后的兒童，出現惡心和嘔吐的副作用，甚者還出現脫水和其他并發癥。
　　研究人員表示，這項研究并沒有特別針對目前全面爆發的甲流感，臨床實驗結果證明，對于感染了新H1N1A型流感的兒童而言，新藥laninamivir收效甚微。

Biota is a leading anti-infective drug development company, based in Melbourne, Australia and Oxford, UK.

Biota's initial success was the discovery of zanamivir, the first-in-class neuraminidase inhibitor for the treatment and prevention of influenza. Zanamivir is licensed to GlaxoSmithKline and marketed as Relenza?. Relenza is used to treat seasonal influenza and is currently being stockpiled by various governments for defence against possible pandemic outbreaks of influenza.

Biota also has key partnerships with:

Boehringer Ingelheim: where it has a licence and collaboration agreement to develop and commercialise Biota's novel nucleoside analogues, designed to treat hepatitis C virus (HCV) infections and potentially other diseases.
Daiichi Sankyo: for the development of second generation influenza antivirals (called LANI or long-acting inhaled neuraminidase inhibitors).
In 2009:

Phase IIa clincial trials of its lead human rhinovirus (HRV) drug achieved clinical proof-of-concept. The drug is aimed at prevention and treatment of one of the major causes of the common cold which is also throught to be a major cause of exacerbations in patients with chronic obstructive pulmonary disease and asthma.
Phase III trials for laninamivir in Asia were shown to be effective. Daiichi Sankyo, who co-own the LANI program have elected to market the drug in Japan.
Biota expanded its antibacterial interests following the asset acquisitions of Prolysis Limited and MaxThera Inc.
The Company's research pipeline includes other earlier stage, small molecule anti-infective programs focused on diseases of significant medical need, such as hepatitis C, respiratory syncytial virus, human cytomegalovirus and new classes of DNA antibiotics to treat hospital-acquired and community-associated infections.

Biota is listed on the Australian Stock Exchange (ASX:BTA).